PReS-FINAL-2055: Is there a necessity for patients with JIA to wear orthopedic insoles?
نویسندگان
چکیده
منابع مشابه
PReS-FINAL-2055: Is there a necessity for patients with JIA to wear orthopedic insoles?
Introduction It is often discussed whether patients with juvenile idiopathic arthritis (JIA) should wear orthopedic insoles or not. The functions of insoles are to minimize pain or to assist foot deformities. JIA often goes along with foot impairments [1,2] describe different deviation and deformities which can develop of various pattern of foot joint involvements, like pes valgoplanus or hallu...
متن کاملPReS-FINAL-2057: Systemic onset JIA with coronary artery dilatation
Objectives A 2-year old boy had been treated as incomplete KD by 2 gr/kg/day of IVIG and 80 mg/kg/day of aspirin at a general pediatrics clinic. From his previous data it was learned that, fever was present for 24 days and it was peaking two to three times a day. He had had a faint rash, arthralgia and lymphadenopathy during follow-up period. But he had’t got conjuctivitis or extremity changes....
متن کاملPReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
Methods Eighty-five (85) patients with JIA receiving etanercept in combination with MTX (etanercept/MTX) and 71 patients receiving MTX alone were enrolled at the Division of Rheumatology, Bambino Gesù Children’s Hospital, Rome, Italy. Incidence rates were calculated as the number of varicella cases, herpes zoster episodes and herpes labialis episodes per patient-years of follow-up (under specif...
متن کاملPReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
Methods Seven children in the age range 2-12 years (mean 6.3 years) with disease duration 1.2 9 years (mean 4.6 years) with active persistent sJIA have been enrolled in one-year prospective study. All 7 patients had oligoarticular joint involvement and received previous treatment with NSAIDS, Methotrexate and corticosteroids. 4/7 had concomitant therapy with Etanercept and 2/7 second DMARD. In ...
متن کاملPReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
Results The follow-up time of the patients was altogether 1516 patient-years (py): 710 for etanercept, 591 for infliximab, 188 for adalimumab, and 27 for other biologic drugs. 216 (62%) patients were female. Median age at onset of JIA was 4.7 years (0.7 to 15.9). Anti-TNF therapy was started at a median age of 10.8 years (2.2 to 19.2). All patients had either received DMARDs prior to anti-TNF o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2013
ISSN: 1546-0096
DOI: 10.1186/1546-0096-11-s2-p68